A Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 18 Mar 2019
Price : $35 *
At a glance
- Drugs Filanesib (Primary) ; Filgrastim; Granulocyte colony-stimulating factors
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms AfFIRM
- Sponsors Array BioPharma
- 04 Oct 2017 The study has been completed in Belgium.
- 29 Sep 2017 Status changed from active, no longer recruiting to completed.
- 12 Dec 2016 Status changed from completed to active, no longer recruiting.